Skip to Content
Read about colorectal cancer treatments here >

Peginterferon alfa-2b Disease Interactions

There are 20 disease interactions with peginterferon alfa-2b:

Major

Interferon Alfa (Includes Peginterferon alfa-2b) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy. Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also be reported. Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction. Renal function should be evaluated in all patients before initiation of interferon- alfa therapy. In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance. A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Major

Interferon- Alfa (Includes Peginterferon alfa-2b) ↔ Autoimmune Diseases

Severe Potential Hazard, Moderate plausibility

Applies to: Autoimmune Disorder

Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis. Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Major

Interferons (Includes Peginterferon alfa-2b) ↔ Cardiac Disease

Severe Potential Hazard, High plausibility

Applies to: Arrhythmias, Congestive Heart Failure, Ischemic Heart Disease, Cardiovascular Disease

Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.

References

  1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.
  3. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
View all 4 references
Major

Interferons (Includes Peginterferon alfa-2b) ↔ Cns Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Seizures, Psychosis, Parkinsonism

Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.

References

  1. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
  2. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  3. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
View all 4 references
Major

Interferons (Includes Peginterferon alfa-2b) ↔ Depression

Severe Potential Hazard, Moderate plausibility

Applies to: Depression

Interferons (alfa or beta) can induce depression and suicidal behavior. Suicidal attempts and suicides have been reported. Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression. Clinical monitoring of psychological status is recommended.

References

  1. "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.
  2. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
  3. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
View all 4 references
Major

Interferons (Includes Peginterferon alfa-2b) ↔ Thyroid Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Thyroid Disease

Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons. Therapy with interferons should be administered cautiously to patients with thyroid dysfunction. If thyroid control can not be maintained within normal limits with medication, interferon-alfa should be discontinued. Clinical monitoring of thyroid function is recommended.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Major

Peginterferon Alfa (Includes Peginterferon alfa-2b) ↔ Autoimmune Hepatitis

Severe Potential Hazard, Moderate plausibility

Applies to: Autoimmune Hepatitis

The use of peginterferons alfa are contraindicated in patients with autoimmune hepatitis.

Major

Peginterferon Alfa (Includes Peginterferon alfa-2b) ↔ Depression

Severe Potential Hazard, High plausibility

Applies to: Depression

Life-threatening or fatal neuropsychiatric reactions have been reported in patients receiving peginterferons alfa, including suicide, suicide ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose. These reactions have occurred in patients with and without previous psychiatric illness. These drugs should be used with extreme caution in patients with a history of depression. Other events reported include aggressive behavior, psychosis, hallucinations, bipolar disorder and mania. Patients should be monitored for any evidence of depression or other psychiatric symptoms, and they should be advised to report any signs or symptoms of depression or other changes in mood or behavior. In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.

Major

Peginterferon Alfa (Includes Peginterferon alfa-2b) ↔ Severe Hepatic Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Cirrhosis, HIV Infection

The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.

Major

Peginterferon Alfa-2B (Includes Peginterferon alfa-2b) ↔ Hemoglobinopathies

Severe Potential Hazard, Moderate plausibility

Applies to: Thalassemia, Sickle Cell Anemia, Hemoglobinopathy

The use of peginterferon alfa-2b is contraindicated in patients with hemoglobinopathies such as, thalassemia major, and sickle-cell anemia.

Major

Peginterferon Alfa-2B (Includes Peginterferon alfa-2b) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The use of peginterferon alfa-2b is contraindicated in patients with creatinine clearance less than 50 mL/min.

Moderate

Interferon Alfa (Includes Peginterferon alfa-2b) ↔ Colitis

Moderate Potential Hazard, Moderate plausibility

Applies to: Ulcerative Colitis

Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment. Abdominal pain, bloody diarrhea, and fever are the typical manifestations. Treatment should be discontinued immediately in patients who develop these signs and symptoms. The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.

Moderate

Interferon Alfa (Includes Peginterferon alfa-2b) ↔ Diabetes Mellitus

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients. Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus. Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Moderate

Interferons (Includes Peginterferon alfa-2b) ↔ Myelosuppression

Moderate Potential Hazard, Moderate plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression. Leukopenia is the primary manifestation. Thrombocytopenia and anemia occur less frequently. Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression. Clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Moderate

Interferons (Includes Peginterferon alfa-2b) ↔ Peripheral Neuropathy

Moderate Potential Hazard, Moderate plausibility

Applies to: Peripheral Neuropathy

Paresthesia and numbness have been reported during interferon therapy. Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.

References

  1. "Product Information. Infergen (interferon alfacon-1)." Amgen, Thousand Oaks, CA.
  2. "Product Information. Intron A (interferon alfa-2b)." Schering Laboratories, Kenilworth, NJ.
Moderate

Peginterferon Alfa (Includes Peginterferon alfa-2b) ↔ Bone Marrow Suppression

Moderate Potential Hazard, Moderate plausibility

Applies to: Thrombocytopenia, Anemia

Peginterferons alfa suppress bone marrow function and may result in severe cytopenias. Very rarely, it may be associated with aplastic anemia. These drugs should be used with caution in patients with baseline neutrophil counts less than 1,500 cells/mm3, with platelet counts less than 90,000 cells/mm3 or baseline hemoglobin less than 10 g/dL. It is advised that complete blood counts be obtained pretreatment and monitored routinely during therapy. Neutropenia and thrombocytopenia occur with greater incidence in patients coinfected with HIV.

Moderate

Peginterferon Alfa (Includes Peginterferon alfa-2b) ↔ Endocrine Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Thyroid Disease, Diabetes Mellitus, Hypoglycemia

Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus. Treatment should be administered with caution on patients with these conditions. Treatment should not be initiated if the condition cannot be effectively treated by medication. Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.

Moderate

Peginterferon Alfa (Includes Peginterferon alfa-2b) ↔ Ophthalmological Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Visual Defect/Disturbance, Retinal Disorder

Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons. All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders. Patients should have periodic ophthalmologic exams during treatment.

Moderate

Peginterferon Alfa (Includes Peginterferon alfa-2b) ↔ Pancreatitis

Moderate Potential Hazard, Moderate plausibility

Applies to: Pancreatitis

Fatal and nonfatal pancreatitis has been observed in patients treated with alpha interferon. Therapy should be suspended in patients with signs and symptoms suggestive of pancreatitis and discontinued in patients diagnosed with pancreatitis.

Moderate

Peginterferon Alfa (Includes Peginterferon alfa-2b) ↔ Pulmonary Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Pulmonary Impairment

Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy. Caution should be used when used in patients with preexisting pulmonary disorders.

peginterferon alfa-2b drug Interactions

There are 190 drug interactions with peginterferon alfa-2b

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide